文献速递造血干细胞移植与细胞治疗淋巴瘤白血病

帕博利珠单抗治疗异基因造血干细胞移植后疾病复发

Pembrolizumab for the treatment of disease relapse after allogeneic hematopoietic stem cell transplantation.
PubMed 文献 · Blood Adv · 2023-01-01

该前瞻性研究评估帕博利珠单抗(200 mg 每 3 周,最长 2 年)治疗异基因造血干细胞移植后复发患者的安全性和疗效,共纳入 12 例患者。3 例(25%)发生 3~4 级免疫相关不良事件,均在 1~2 周期后出现,停药和皮质类固醇治疗后缓解;未观察到治疗中新发 GVHD。总体缓解率和完全缓解率均为 22%(2/9),两例完全缓解患者均为 PD-L1 基因扩增的淋巴瘤且治疗前活检显示弥漫 PD-L1 表达。

要点

  • 12 例异基因造血干细胞移植后复发患者接受帕博利珠单抗 200 mg 每 3 周治疗,最长 2 年。
  • 3 例(25%)发生 3~4 级免疫相关不良事件(肺炎 2 例、甲状腺功能亢进 1 例),均在 1~2 周期后出现并经停药和皮质类固醇治疗缓解。
  • 总体缓解率和完全缓解率均为 22%(2/9),两例完全缓解患者均为 PD-L1 基因扩增淋巴瘤且治疗前活检显示弥漫 PD-L1 表达。

核心结论

  • 异基因造血干细胞移植后使用帕博利珠单抗可行,在复发性淋巴系统恶性肿瘤中可观察到客观缓解,但可诱发严重免疫相关不良事件,需要警惕监测。

研究设计与样本

  • 前瞻性研究,评估帕博利珠单抗在异基因造血干细胞移植后复发患者中的安全性和疗效,共纳入 12 例患者。
  • 纳入患者包括急性髓系白血病 8 例、骨髓增生异常综合征 1 例、经典型霍奇金淋巴瘤 1 例、弥漫大 B 细胞淋巴瘤(DLBCL)2 例。
  • 所有参与者均接受减低强度预处理方案联合体内 T 细胞去除。
  • 从异基因造血干细胞移植至入组的中位时间为 587 天(范围 101~4211 天)。
  • eligible 患者接受帕博利珠单抗 200 mg 每 3 周,最长 2 年。

主要发现

  • 3 例参与者(25%)发生 3~4 级免疫相关不良事件(肺炎 2 例、甲状腺功能亢进 1 例),均在 1~2 周期后出现,经停用帕博利珠单抗和皮质类固醇治疗后缓解。
  • 任何级别免疫相关不良事件发生于 5 例患者(42%)。
  • 未观察到治疗中新发移植物抗宿主病(GVHD)。
  • 总体缓解率和完全缓解率均为 22%(2/9)。
  • 两例达到完全缓解的患者均为 PD-L1 基因扩增淋巴瘤,且治疗前活检显示弥漫 PD-L1 表达。

关键数值与推荐

  • 帕博利珠单抗给药方案为 200 mg 每 3 周,最长 2 年。
  • 3~4 级免疫相关不良事件发生率为 25%(3/12),任何级别免疫相关不良事件发生率为 42%(5/12)。
  • 总体缓解率和完全缓解率均为 22%(2/9)。

临床怎么用

  • 异基因造血干细胞移植后复发患者使用帕博利珠单抗可行,在复发性淋巴系统恶性肿瘤中可观察到客观缓解,但可诱发严重免疫相关不良事件,需要警惕监测。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

A failed graft-versus-tumor (GVT) effect is a common mechanism of relapse after allogeneic hematopoietic cell transplantation (alloHCT). Although targeting the PD-1/PD-L1 axis may restore GVT effects, PD-1 blockade exacerbates graft-versus-host disease (GVHD) in murine models, and severe GVHD can occur in patients treated with anti-PD-1 therapy after alloHCT. Therefore, we developed a prospective study to assess the safety and efficacy of pembrolizumab in patients relapsing after alloHCT. Eligible patients received pembrolizumab (200 mg every 3 weeks) for up to 2 years. Twelve patients were enrolled (8 patients with acute myeloid leukemia, 1 patient with myelodysplastic syndrome, 1 patient with classical Hodgkin lymphoma, and 2 patients with diffuse large B-cell lymphoma [DLBCL]). All participants received reduced-intensity preparative regimens with in vivo T-cell depletion. The median time from alloHCT to enrollment was 587 days (range, 101-4211). Three participants (25%) experienced grade 3 to 4 immune-related adverse events (irAE) (pneumonitis, 2 patients; hyperthyroidism, 1 patient), all occurring after 1 to 2 cycles, and resolving after pembrolizumab discontinuation and corticosteroid treatment. irAEs of any grade occurred in 5 patients (42%). No treatment-emergent GVHD was observed. Overall and complete response (CR) rates were 22% (2/9). Both patients achieving CRs had PD-L1 gene-amplified lymphomas and diffuse PD-L1 expression on pretreatment biopsies. An acquired EZH2 mutation was identified at relapse in a patient with DLBCL who achieved an initial CR to pembrolizumab, which was associated with downregulated HLA expression on malignant B cells, implicating EZH2 mutations as a potential immune escape mechanism after PD-1-blockade therapy. In conclusion, after alloHCT, treatment with pembrolizumab is feasible and associated with objective responses in relapsed lymphoid malignancies but can induce severe irAEs, requiring vigilant monitoring. This trial was registered at www.clinicaltrials.gov as #NCT02981914.

来源:Blood Adv,查看原文。版权归原作者所有。

引用

  1. Godfrey J, Liu H, Yu J, et al. Pembrolizumab for the treatment of disease relapse after allogeneic hematopoietic stem cell transplantation. Blood Adv. 2023. PMID: 35973200. doi:10.1182/bloodadvances.2022008403

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。